MaxCyte Q1 Revenue $9.65M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Reports Q1 revenue $9.65M, consensus $7.3M. "We are pleased with our performance in the first quarter, and remain confident in our full year guidance," said Maher Masoud, President and CEO of MaxCyte. "Our core revenue from partners and customers was in line with our expectations for both our ExPERT electroporation platforms and SeQure services. The SPL portfolio continues to advance in the clinic, including a clinical customer that began dosing patients in a registrational study in the first quarter, and we remain confident additional customers will initiate registrational trials this year. Further, our SPL portfolio remains strong and spans a broad range of modalities and indications. MaxCyte remains extremely well positioned in the cell & gene therapy industry, with leading technology and an efficient cost structure. Reflecting continued confidence in our strategy and the long-term value of our business, the Board today authorized a $10 million share repurchase. This authorization provides us with flexibility in capital allocation while we continue to invest in key growth initiatives, including the recent launch of ExPERT DTx and the integration of SeQure Dx. We believe this balanced approach enables us to both reinvest in the business and return capital to shareholders."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MXCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MXCT
Wall Street analysts forecast MXCT stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.000
Low
4.94
Averages
6.92
High
8.89
Current: 1.000
Low
4.94
Averages
6.92
High
8.89
About MXCT
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MaxCyte Q1 2026 Earnings Call Insights
- Revenue Overview: MaxCyte reported total revenue of $9.7 million for Q1 2026, including $6.2 million in core revenue and $3.4 million from SPL program-related activities, indicating that while results met expectations, challenges from inventory management by its largest customer and discontinued SPL programs are impacting short-term performance.
- Future Outlook: Management reiterated its full-year revenue guidance of $30 million to $32 million, with core revenue expected to range from $25 million to $27 million, and core revenue for Q2 anticipated to be in line with Q1, suggesting a positive outlook for growth in the second half of the year.
- Share Repurchase Program: MaxCyte announced a $10 million share repurchase authorization, intending to execute the majority of this program by year-end, which aims to enhance shareholder value and reflects the company's confidence in future cash flows.
- Market Dynamics: Vertex reported approximately $43 million in revenue from its Casgevy product in Q1 2026, with over 500 patients initiating treatment, indicating strong momentum in commercial royalties for MaxCyte, potentially laying the groundwork for future revenue growth.
See More
MaxCyte Q4 2025 Earnings Call Insights
- Revenue Decline: MaxCyte reported total revenue of $33 million for 2025, a 15% decrease from $38.6 million in 2024, with core revenue at $29.6 million, indicating significant challenges and revenue pressure in the market.
- New Product Launch: The company launched the ExPERT DTx platform aimed at accelerating early-stage research and drug discovery, despite facing a $4 million revenue headwind from customer program consolidation, with 2026 total revenue guidance set between $30 million and $32 million.
- Management Changes: Parmeet Ahuja will succeed Doug Swirsky as Chief Financial Officer effective March 30, reflecting strategic adjustments in the executive team to address current market challenges.
- Cash Position: As of the end of 2025, MaxCyte had total cash and cash equivalents and investments of $155.6 million with no debt, demonstrating financial stability that supports future growth initiatives.
See More
MaxCyte Reports 2025 Revenue Decline Amid Strategic Developments
- Revenue Decline: MaxCyte's total revenue for 2025 was $33 million, reflecting a 15% decline from 2024, indicating financial challenges primarily due to customer program consolidations, with expectations of continued core revenue decline in 2026.
- Core Revenue Drop: The core revenue for 2025 stood at $29.6 million, a 9% decrease year-over-year, with Q4 core revenue at $6.8 million, down 22% from Q4 2024, highlighting competitive pressures in the market.
- High Gross Margin: Despite the revenue decline, MaxCyte achieved a gross margin of 78% in Q4 2025, up from 74% in Q4 2024, demonstrating effective cost management strategies that could support future profitability.
- Financial Flexibility: By the end of 2025, MaxCyte maintained $155.6 million in cash with no debt, providing financial flexibility that supports future strategic investments and business development initiatives.
See More
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript
See More
MaxCyte Q4 Earnings Miss Expectations
- Disappointing Earnings: MaxCyte reported a Q4 GAAP EPS of -$0.09, missing expectations by $0.01, indicating challenges in profitability that may affect investor confidence.
- Revenue Decline: The company’s Q4 revenue of $7.3 million represents a 16.1% year-over-year decline, falling short by $1.86 million, reflecting pressures from weak market demand and increased competition.
- Full-Year Revenue Guidance: MaxCyte expects full-year revenue to range between $30 million and $32 million, with core revenue projected at $25 million to $27 million and SPL program-related revenue around $5 million, indicating ongoing investment in specific areas.
- Milestone Payments and Royalties: The SPL program-related revenue guidance includes approximately $3 million from milestone payments and about $2 million from commercial royalties, highlighting the company’s strategic focus on new product development and market penetration.
See More
MAXCYTE INC PROJECTS CORE REVENUE BETWEEN $25 MILLION AND $27 MILLION FOR 2026
Revenue Projection: The core revenue for MAXCYT is projected to increase from $25 million to $27 million by 2026.
Financial Outlook: This outlook indicates a positive growth trend for the company in the coming years.
See More
MaxCyte Q1 2026 Earnings Call Insights
- Revenue Overview: MaxCyte reported total revenue of $9.7 million for Q1 2026, including $6.2 million in core revenue and $3.4 million from SPL program-related activities, indicating that while results met expectations, challenges from inventory management by its largest customer and discontinued SPL programs are impacting short-term performance.
- Future Outlook: Management reiterated its full-year revenue guidance of $30 million to $32 million, with core revenue expected to range from $25 million to $27 million, and core revenue for Q2 anticipated to be in line with Q1, suggesting a positive outlook for growth in the second half of the year.
- Share Repurchase Program: MaxCyte announced a $10 million share repurchase authorization, intending to execute the majority of this program by year-end, which aims to enhance shareholder value and reflects the company's confidence in future cash flows.
- Market Dynamics: Vertex reported approximately $43 million in revenue from its Casgevy product in Q1 2026, with over 500 patients initiating treatment, indicating strong momentum in commercial royalties for MaxCyte, potentially laying the groundwork for future revenue growth.
See More
MaxCyte Q4 2025 Earnings Call Insights
- Revenue Decline: MaxCyte reported total revenue of $33 million for 2025, a 15% decrease from $38.6 million in 2024, with core revenue at $29.6 million, indicating significant challenges and revenue pressure in the market.
- New Product Launch: The company launched the ExPERT DTx platform aimed at accelerating early-stage research and drug discovery, despite facing a $4 million revenue headwind from customer program consolidation, with 2026 total revenue guidance set between $30 million and $32 million.
- Management Changes: Parmeet Ahuja will succeed Doug Swirsky as Chief Financial Officer effective March 30, reflecting strategic adjustments in the executive team to address current market challenges.
- Cash Position: As of the end of 2025, MaxCyte had total cash and cash equivalents and investments of $155.6 million with no debt, demonstrating financial stability that supports future growth initiatives.
See More
MaxCyte Reports 2025 Revenue Decline Amid Strategic Developments
- Revenue Decline: MaxCyte's total revenue for 2025 was $33 million, reflecting a 15% decline from 2024, indicating financial challenges primarily due to customer program consolidations, with expectations of continued core revenue decline in 2026.
- Core Revenue Drop: The core revenue for 2025 stood at $29.6 million, a 9% decrease year-over-year, with Q4 core revenue at $6.8 million, down 22% from Q4 2024, highlighting competitive pressures in the market.
- High Gross Margin: Despite the revenue decline, MaxCyte achieved a gross margin of 78% in Q4 2025, up from 74% in Q4 2024, demonstrating effective cost management strategies that could support future profitability.
- Financial Flexibility: By the end of 2025, MaxCyte maintained $155.6 million in cash with no debt, providing financial flexibility that supports future strategic investments and business development initiatives.
See More
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript
See More
MaxCyte Q4 Earnings Miss Expectations
- Disappointing Earnings: MaxCyte reported a Q4 GAAP EPS of -$0.09, missing expectations by $0.01, indicating challenges in profitability that may affect investor confidence.
- Revenue Decline: The company’s Q4 revenue of $7.3 million represents a 16.1% year-over-year decline, falling short by $1.86 million, reflecting pressures from weak market demand and increased competition.
- Full-Year Revenue Guidance: MaxCyte expects full-year revenue to range between $30 million and $32 million, with core revenue projected at $25 million to $27 million and SPL program-related revenue around $5 million, indicating ongoing investment in specific areas.
- Milestone Payments and Royalties: The SPL program-related revenue guidance includes approximately $3 million from milestone payments and about $2 million from commercial royalties, highlighting the company’s strategic focus on new product development and market penetration.
See More
MAXCYTE INC PROJECTS CORE REVENUE BETWEEN $25 MILLION AND $27 MILLION FOR 2026
Revenue Projection: The core revenue for MAXCYT is projected to increase from $25 million to $27 million by 2026.
Financial Outlook: This outlook indicates a positive growth trend for the company in the coming years.
See More
